Research Topics
Genomes and GenesSpecies | T BatchelorSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
High-dose methotrexate for isolated central nervous system relapse in patients with testicular non-Hodgkin's lymphomaT Batchelor
Brain Tumor Center, Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA
Clin Lymphoma 2:116-9; discussion 120-2. 2001..These patients were treated with high-dose intravenous methotrexate alone, and a complete remission was achieved in all 4 patients...- Primary CNS lymphomaTracy Batchelor
Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Oncol 24:1281-8. 2006..The risk of neurotoxicity is lower in patients treated with chemotherapy alone... 
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patientsTracy T Batchelor
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Cancer Cell 11:83-95. 2007..Our study provides insight into different mechanisms of action of this class of drugs in recurrent glioblastoma patients and suggests that the timing of combination therapy may be critical for optimizing activity against this tumor...- Neuro-oncology update: 2005Tracy Batchelor
Department of Neurology, Harvard Medical School, Neurology Service and Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital, Boston, MA 02114, USA
Curr Opin Neurol 18:631. 2005 - Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastomaTracy T Batchelor
Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit St, Boston, MA 02114, USA
J Clin Oncol 28:2817-23. 2010..Glioblastoma is an incurable solid tumor characterized by increased expression of vascular endothelial growth factor (VEGF). We performed a phase II study of cediranib in patients with recurrent glioblastoma... - Supportive care of brain tumor patientsTracy T Batchelor
Department of Neurology, Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
Hematol Oncol Clin North Am 20:1337-61. 2006..Effective treatment is usually possible, however, and can result in an improved quality of life for these patients... - Age-dependent prognostic effects of genetic alterations in glioblastomaTracy T Batchelor
Molecular Neuro oncology Laboratory, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 10:228-33. 2004..Although the genetic alterations in glioblastoma have been well characterized, reports regarding their prognostic effects have been inconsistent... - Clinical trials in neuro-oncologyT Batchelor
Department of Neurology, Harvard Medical School, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
Curr Opin Neurol 14:689-94. 2001..This review begins with enumeration of the basic principles of clinical trial design including reduction of bias and variability, and concludes with a review of study design factors of particular relevance for neuro-oncology... - Primary nervous system lymphomaScott R Plotkin
Brain Tumor Center, Cox 315, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA
Curr Treat Options Oncol 3:525-35. 2002..Given the rarity of this tumor, patients with PNSL should be referred to tertiary cancer centers where ongoing clinical trials are underway to identify the optimal treatment of PNSL... - Long-term outcome in PCNSL patients treated with high-dose methotrexate and deferred radiationElizabeth R Gerstner
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Neurology 70:401-2. 2008 - Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in miceWalid S Kamoun
Edwin L Steele Laboratory, Department of Radiation Oncology, Stephen E and Catherine Pappas Center for Neuro Oncology, and AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Oncol 27:2542-52. 2009..Our goal was to determine whether alleviation of edema by anti-VEGF agents alone could increase survival in mice... - Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adultsSantosh Kesari
Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney St, SW430D, Boston, MA 02115, USA
Neuro Oncol 10:300-8. 2008..07) and PFS (p=0.09). The addition of celecoxib and thalidomide to adjuvant temozolomide was well tolerated but did not meet the primary end point of improvement of 4-month PFS from study enrollment... - A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patientsA Gregory Sorensen
A A Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Boston, MA 02114, USA
Cancer Res 69:5296-300. 2009..54; P = 0.004) and progression-free survival (rho = 0.6; P = 0.001). The vascular normalization index described here should be validated in randomized clinical trials... 
Angiogenesis as a therapeutic target in malignant gliomasAndrew S Chi
Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
Oncologist 14:621-36. 2009..Although challenges remain with this approach, ongoing studies may improve upon the promising initial benefits already observed in GBM patients...- Genetic analyses for predictors of radiation response in glioblastomaHelen A Shih
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Int J Radiat Oncol Biol Phys 63:704-10. 2005.... - Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphomaPaul L Nguyen
Massachusetts General Hospital, Department of Radiation Oncology, 100 Blossom St, Boston, MA 02114, USA
J Clin Oncol 23:1507-13. 2005..9 months. Age less than 60 years and response to WBRT predict post-WBRT survival. Modest rates of late neurotoxicity (15%) were seen and were associated with a total dose greater than 36 Gy... - Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adultsSantosh Kesari
Center for Neuro Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Neuro Oncol 9:354-63. 2007..While metronomic chemotherapy may not be useful in patients with advanced disease, further studies using metronomic chemotherapy combined with more potent antiangiogenic agents in patients with less advanced disease may be warranted... - Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survivalMasahiro Mizoguchi
Molecular Pathology Unit and Molecular Neuro-Oncology Laboratory, Department of Pathology, Cancer Center and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA
J Neuropathol Exp Neurol 65:1181-8. 2006..Taken together, these findings begin to elucidate the interrelationship between these signaling pathways in astrocytic gliomas in vivo... - Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastomaJan Drappatz
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Boston, MA 02115, USA
Int J Radiat Oncol Biol Phys 78:85-90. 2010..We conducted a Phase I study of vandetanib, an inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor, in patients with newly diagnosed GBM combined with RT and temozolomide (TMZ)... - Angiogenesis in brain tumoursRakesh K Jain
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, Massachusetts 02114, USA
Nat Rev Neurosci 8:610-22. 2007..This creates a window of opportunity for optimally combining chemotherapeutics and radiation... - Genome-wide comparison of paired fresh frozen and formalin-fixed paraffin-embedded gliomas by custom BAC and oligonucleotide array comparative genomic hybridization: facilitating analysis of archival gliomasGayatry Mohapatra
Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
Acta Neuropathol 121:529-43. 2011..In combination, these advances should facilitate genome-wide analysis of rare, small and/or histologically heterogeneous gliomas from FFPE tissues... - The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastomaDavid J Sher
Harvard Radiation Oncology Program, Boston, MA, USA
J Neurooncol 88:43-50. 2008..We sought to determine the relative contribution of concomitant temozolomide in patients treated by concurrent and adjuvant TMZ versus adjuvant TMZ alone in the setting of newly diagnosed GBM... - VEGF inhibitors in the treatment of cerebral edema in patients with brain cancerElizabeth R Gerstner
Department of Neurology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Nat Rev Clin Oncol 6:229-36. 2009..Anti-VEGF agents might also be useful in other cancer-related conditions that increase vascular permeability, such as malignant pleural effusions or ascites... - Anti-vascular endothelial growth factor therapy for malignant gliomaElizabeth R Gerstner
Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, 55 Fruit Street, Boston, MA 02114, USA
Curr Neurol Neurosci Rep 9:254-62. 2009..However, because most patients eventually relapse, more work is needed to understand mechanisms of disease escape, including vascular co-option of native brain blood vessels... - High-dose methotrexate for elderly patients with primary CNS lymphomaJay Jiguang Zhu
Department of Neurology, Tufts New England Medical Center, Boston, MA, USA
Neuro Oncol 11:211-5. 2009..High-dose MTX should be considered as a feasible treatment option in elderly patients with PCNSL... - Leptomeningeal neoplasmsJan Drappatz
Jan Drappatz, MD Harvard Medical School, Department of Neurology, Brigham and Women s Hospital and Dana Farber Brigham and Women s Cancer Center, Center for Neuro Oncology, 44 Binney Street SW 430, Boston, MA 02115, USA
Curr Treat Options Neurol 9:283-93. 2007..There is hope that progress in diagnostic modalities and the development of more effective intrathecal antineoplastic drugs may decrease neurologic morbidity and improve quality of life and survival... - CNS Hodgkin lymphomaElizabeth R Gerstner
Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Blood 112:1658-61. 2008.... - Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatmentDaniel P Cahill
Molecular Pathology Unit, Neurosurgical Service, Brain Tumor Center, and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Clin Cancer Res 13:2038-45. 2007..However, the extent of involvement of MSH6 in glioblastoma is unknown. We sought to determine the overall frequency and clinical relevance of MSH6 alterations in glioblastomas... - Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
Clin Cancer Res 10:5643-6. 2004..The optimal management of these patients has not been determined. We performed a multicenter, retrospective study of high-dose methotrexate in patients with relapsed central nervous system lymphoma... - Imaging and response criteria in gliomasElizabeth R Gerstner
Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Curr Opin Oncol 22:598-603. 2010..These new techniques are increasingly being incorporated into clinical trials and even into clinical practice. Therefore, it is important to be familiar with the available imaging techniques and their potential uses versus limitations... - Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranibElizabeth R Gerstner
Departments of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
Neuro Oncol 12:466-72. 2010..ADC maps can be used to suggest regions of infiltrative tumor cells with anti-VEGF therapy and should be validated in future studies... - Primary central nervous system lymphomaElizabeth R Gerstner
Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA
Arch Neurol 67:291-7. 2010..Unfortunately, although durable remissions may be achieved for some patients with PCNSL, the tumor relapses in most cases. In this review, we will focus on PCNSL in the immunocompetent host... - Vascular endothelial growth factor inhibitors in malignant gliomasPriscilla K Brastianos
Stephen E and Catherine Pappas Center for Neuro Oncology, Department of Neurology, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, MA, USA
Target Oncol 5:167-74. 2010..Unfortunately, antiangiogenic treatment inevitably fails in most patients. Further studies are needed to understand the molecular pathways that enable a tumor to evade antiangiogenic therapy... - BCL-6 expression predicts improved survival in patients with primary central nervous system lymphomaKristina M Braaten
Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Clin Cancer Res 9:1063-9. 2003..CONCLUSIONS: In this group of 33 patients with PCNSL, expression of BCL-6 was significantly associated with longer overall survival. BCL-6 warrants further investigation as a potentially important prognostic marker in this disease... - High-dose methotrexate for intraocular lymphomaTracy T Batchelor
Massachusetts General Hospital Brain Tumor Center and Neurology Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Clin Cancer Res 9:711-5. 2003..We also sought to determine whether micromolar levels of MTX could be achieved in the aqueous and vitreous humor of the eye after i.v. administration of the drug... - Peripheral and cranial nerve sheath tumorsMaciej M Mrugala
Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Curr Opin Neurol 18:604-10. 2005..Vestibular schwannomas, neurogenetic syndromes such as schwannomatosis and multiple isolated neurofibromas, and malignant peripheral nerve sheath tumors are covered in this review... - Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastomaManish Aghi
Neurosurgical Service, Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
Clin Cancer Res 11:8600-5. 2005..EGFR overexpression correlates in experimental gliomas with increased angiogenesis, edema, and invasion. No radiographic predictors of molecular glioblastoma subtype are known... - Cediranib: profile of a novel anti-angiogenic agent in patients with glioblastomaJörg Dietrich
Stephen E and Catherine Pappas Center for Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Expert Opin Investig Drugs 18:1549-57. 2009..Treatment strategies targeting angiogenesis have revealed promising results in preclinical studies and early clinical trials in patients with glioblastomas... - Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patientsScott R Plotkin
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, U S A
Otol Neurotol 31:1135-43. 2010..We sought to determine the activity of erlotinib for progressive vestibular schwannoma (VS) associated with neurofibromatosis 2 (NF2)... - Advances in neuroimaging techniques for the evaluation of tumor growth, vascular permeability, and angiogenesis in gliomasElizabeth R Gerstner
Department of Neurology, Division of Neuro Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA
Curr Opin Neurol 21:728-35. 2008..This review will summarize new neuroimaging techniques, particularly MRI and PET imaging, that can be used to assess brain tumor growth and angiogenesis... - A pilot safety study of lenalidomide and radiotherapy for patients with newly diagnosed glioblastoma multiformeJan Drappatz
Center for Neuro Oncology, Dana Farber Brigham and Women s Cancer Center, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
Int J Radiat Oncol Biol Phys 73:222-7. 2009.... - Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11Tracy T Batchelor
Brain Tumor Center, Massachusetts General Hospital, Boston, MA 02114, USA
Neuro Oncol 6:21-7. 2004..Irinotecan had minimal efficacy in this cohort of 18 patients with recurrent malignant glioma. Toxicity was significant but similar to that reported in other patient populations... - Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-2005. A 35-year-old woman with difficulty walking, headache, and nauseaTracy T Batchelor
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, USA
N Engl J Med 352:185-94. 2005 - Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexateApril F Eichler
Pappas Center for Neuro Oncology, Boston, MA 02114, USA
Neuro Oncol 9:373-7. 2007..The absence of vascular or perfusion abnormalities suggests that transient cytotoxic edema in white matter may explain the syndrome of subacute MTX neurotoxicity... - VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospectsDan G Duda
Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital, 100 Blossom Street, COX 734, Boston, MA 02114, USA
Trends Mol Med 13:223-30. 2007.... - Biomarkers of response and resistance to antiangiogenic therapyRakesh K Jain
Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Nat Rev Clin Oncol 6:327-38. 2009.... - The effect of enzyme-inducing antiseizure drugs on the pharmacokinetics and tolerability of procarbazine hydrochlorideStuart A Grossman
The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Massachusetts General Hospital, Boston, USA
Clin Cancer Res 12:5174-81. 2006..This study was conducted to determine if the maximum tolerated dose and pharmacokinetics of PCB are affected by the concurrent use of enzyme-inducing antiseizure drugs (EIASD)... - Antiangiogenic agents for the treatment of glioblastomaElizabeth R Gerstner
1Massachusetts General Hospital Cancer Center and Harvard Medical School, Department of Neurology, Boston, Massachusetts, USA
Expert Opin Investig Drugs 16:1895-908. 2007..It seems likely that a combination of antiangiogenesis agents with other cytotoxic therapies will be required to achieve maximal efficacy... - Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group ReportS A Grimm
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
Neurology 71:1355-60. 2008..To describe the demographics, diagnostic details, therapeutic management, and outcome in patients with primary CNS lymphoma (PCNSL) with ocular involvement... - Insights into the biology of primary central nervous system lymphomaMaciej M Mrugala
Stephen E and Catherine Pappas Center for Neuro Oncology, Yawkey 9E, Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA
Curr Oncol Rep 11:73-80. 2009..This review discusses recent advances in PCNSL biology, including immunologic and genetic risk factors, and focuses on the molecular alterations important in central nervous system lymphomagenesis... - Response criteria for gliomaA Gregory Sorensen
Harvard Medical School, Boston, MA, USA
Nat Clin Pract Oncol 5:634-44. 2008.... - YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomasCatherine L Nutt
Molecular Neuro Oncology Laboratory and Molecular Pathology Unit, Department of Pathology, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA
Clin Cancer Res 11:2258-64. 2005..Moreover, a combination of YKL-40 and glial fibrillary acidic protein immunohistochemistry afforded even greater diagnostic accuracy in anaplastic oligodendrogliomas... - Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomasGaurav D Shah
Brigham and Women's Hospital, Boston, MA 02115, USA
Neuro Oncol 8:38-46. 2006..Thus, linear methods are comparable to volumetric methods, but simpler to implement for routine clinical use and for designing clinical trials of brain tumors... - Gene expression-based classification of malignant gliomas correlates better with survival than histological classificationCatherine L Nutt
Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
Cancer Res 63:1602-7. 2003..These data suggest that class prediction models, based on defined molecular profiles, classify diagnostically challenging malignant gliomas in a manner that better correlates with clinical outcome than does standard pathology... - VEGF inhibitors in brain tumorsPriscilla K Brastianos
Department of Medical Oncology, Dana Farber Brigham and Women s Cancer Center, Massachusetts General Hospital, Boston, 02114, USA
Clin Adv Hematol Oncol 7:753-60, 768. 2009..Unfortunately, treatment inevitably fails. Further studies are needed to understand mechanisms of tumor resistance and to identify other therapeutic targets that mediate angiogenesis... - Primary central nervous system lymphoma: presentation, diagnosis and stagingApril F Eichler
Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Neurosurg Focus 21:E15. 2006..Testicular ultrasonography studies should be considered in men. In patients who cannot undergo LP or in those with evidence of spinal cord dysfunction, contrast-enhanced MR imaging of the entire spine should be considered... - Malignant peripheral nerve sheath tumor: the clinical spectrum and outcome of treatmentJoachim M Baehring
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Neurology 61:696-8. 2003..Presented is a series of 54 patients with MPNST seen at a single institution over a 10-year period. In this series, tumor diameter of <5 cm, gross total resection of the tumor, and younger age were favorable prognostic variables... - Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphomaLauren E Abrey
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 23:5034-43. 2005..We hope that these guidelines will improve communication among investigators and comparability among clinical trials in a way that will allow us to develop better therapies for patients... - Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: case studyAlfredo D Voloschin
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
Neuro Oncol 7:97-100. 2005..This treatment strategy, although common in the treatment of other solid tumors, is rarely utilized in adult neuro-oncology and raises another potential role for chromosome testing in oligodendroglial tumor management... - Leptomeningeal metastasesSantosh Kesari
Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
Neurol Clin 21:25-66. 2003..This may provide an opportunity for effective intervention that can improve quality of life, prevent further neurologic deterioration and, for a subset of patients, improve survival... - Statistical considerations for immunohistochemistry panel development after gene expression profiling of human cancersRebecca A Betensky
Department of Biostatistics, Harvard School of Public Health, 655 Huntington Ave, Boston, Massachusetts 02115, USA
J Mol Diagn 7:276-82. 2005..Simulation approaches for computing power and sample size that are based on existing gene expression data provide a powerful tool for efficient design of follow-up genomic studies... - Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapyDavid A Reardon
Duke University Medical Center, Neuro Oncology Program, Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA
Expert Opin Biol Ther 8:541-53. 2008..Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors... - International study on low-grade primary central nervous system lymphomaKristoph Jahnke
Department of Hematology, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
Ann Neurol 59:755-62. 2006..The aim of this study was to characterize the clinical presentation, course, and outcome of low-grade primary central nervous system lymphoma... - A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapyChris Hunter
Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom
Cancer Res 66:3987-91. 2006..These observations highlight the potential of large scale sequencing for revealing and elucidating mutagenic processes operative in individual human cancers... - Reversible posterior leukoencephalopathy syndromeAndrew D Norden
Onkologie 30:90-1. 2007
Research Grants
- A Phase 2 study of AZD2171 in Recurrent GlioblastomaTracy Batchelor; Fiscal Year: 2006..Incorporation of these correlative techniques into this phase 2 study represent unique strengths of our institution and will enhance our ability to assess the potential efficacy of AZD2171 in a multidimensional manner. ..
- AZD2171 and chemoradiation for newly diagnosed glioblastomaTracy Batchelor; Fiscal Year: 2009..In Aim 3 we will continue to explore the potential utility of tumor and serial blood biomarkers, including bFGF, SDF1 and CECs, as predictors of tumor response and patient outcome in the newly diagnosed GM population. ..
- AZD2171 and chemoradiation for newly diagnosed glioblastomaTracy Batchelor; Fiscal Year: 2007..In Aim 3 we will continue to explore the potential utility of tumor and serial blood biomarkers, including bFGF, SDF1 and CECs, as predictors of tumor response and patient outcome in the newly diagnosed GM population. ..
- Annual Primary CNS Lymphoma Collaborative Group MeetingTracy Batchelor; Fiscal Year: 2007..Although the group has existed for only 3 years it have fostered international collaboration across multiple disciplines on an unprecedented scale and has had an impact on PCNSL research and clinical care. ..
- Clinical and Molecular Studies of Novel Therapeutics in Malignant Brain TumorsTracy Batchelor; Fiscal Year: 2007....
- NABTT-New Approaches to Brain Tumor Therapy (CNSC)Tracy Batchelor; Fiscal Year: 2007....
- AZD2171 and chemoradiation for newly diagnosed glioblastomaTracy T Batchelor; Fiscal Year: 2010..In Aim 3 we will continue to explore the potential utility of tumor and serial blood biomarkers, including bFGF, SDF1 and CECs, as predictors of tumor response and patient outcome in the newly diagnosed GM population. ..